# Iovance Biotherapeutics

Type: Company (IOVA)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/iovance-biotherapeutics
Canonical HTML page: https://getfinancebrief.com/entity/iovance-biotherapeutics

## Recent coverage (2 stories)

### MarketBeat Screeners Highlight Fitness Recovery and Value Stability
2026-02-26 12:18:51 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

MarketBeat's latest stock screeners identify a diverse range of opportunities across fitness, fintech, and value sectors as investors recalibrate for late Q1. From the resurgence of brick-and-mortar gyms to the defensive positioning of banking giants, these picks reflect a market balancing growth and risk.
Full story: https://getfinancebrief.com/story/fitness-value-stocks-watchlist-february-2026

### Iovance and Fidelity National Set for Q4 Earnings Amid Sector Shifts
2026-02-23 17:01:52 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Iovance Biotherapeutics and Fidelity National Financial are preparing to report Q4 2025 results, with investors focusing on the commercial scaling of cell therapies and the resilience of the title insurance market. These reports will provide critical data on biotech commercialization and the health of the U.S. housing sector.
Full story: https://getfinancebrief.com/story/iovance-fidelity-national-q4-2025-earnings-preview

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.